Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest

Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of a...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Life
المؤلفون الرئيسيون:	Natalia Kirsten, Frenz Ohm, Kathrin Gehrdau, Gefion Girbig, Brigitte Stephan, Nesrine Ben-Anaya, Andreas Pinter, Falk G. Bechara, Dagmar Presser, Christos C. Zouboulis, Matthias Augustin
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2022-09-01
الموضوعات:	hidradenitis suppurativa biologics TNF alpha adverse drug reaction biosimilar drug effectiveness
الوصول للمادة أونلاين:	https://www.mdpi.com/2075-1729/12/10/1518